X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.
Lead Product(s): Lunresertib,Camonsertib
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Repare Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 12, 2024
Details:
FDA granted Fast Track designation to RP-6306 (lunresertib) in combination with RP-3500 (camonsertib) for CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer.
Lead Product(s): Lunresertib,Camonsertib
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2024
Details:
RP-6306 (lunresertib), a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, is being developed in combination with Debio 0123, an oral, brain-penetrant, highly selective WEE1 kinase inhibitor, for the treatment of advanced solid tumors.
Lead Product(s): Lunresertib,Debio0123
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
The collaboration will explore the synergy between Debio 0123, a potential best-in-class, brain-penetrant, and highly selective WEE1 inhibitor, and RP-6306 (lunresertib), a first-in-class, selective and potent oral, small molecule inhibitor of PKMYT1 with anticancer activity.
Lead Product(s): Debio 0123,Lunresertib
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
RP-6306 (lunresertib) is a PKMYT1 inhibitor currently in Phase 1 clinical development a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche.
Lead Product(s): Lunresertib
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canadian Cancer Trials Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
